Aethlon Medical, Inc. (AEMD)
| Market Cap | 3.40M -33.2% |
| Revenue (ttm) | n/a |
| Net Income | -11.52M |
| EPS | -28.51 |
| Shares Out | 1.57M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,306 |
| Open | 2.180 |
| Previous Close | 2.200 |
| Day's Range | 2.140 - 2.200 |
| 52-Week Range | 1.360 - 35.200 |
| Beta | 1.52 |
| Analysts | Hold |
| Price Target | 15.00 (+591.24%) |
| Earnings Date | Feb 12, 2026 |
About AEMD
Aethlon Medical, Inc., a medical therapeutic company, engages in developing novel immunotherapeutic devices to treat cancer and viral infections in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device intended for applications in cancer, and life-threatening viral infections, and use in organ transplantation. The company was founded in 1984 and is based in San Diego, California.
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for AEMD stock is "Hold" and the 12-month stock price target is $15.0.
News
Aethlon Medical Transcript: Emerging Growth Conference 91
An Australian oncology trial is advancing to its final cohort after positive safety review, focusing on optimizing Hemopurifier treatments for patients unresponsive to leading immunotherapies. Data on immune and exosome changes are expected this quarter.
Advancements in Novel Immunotherapeutics in The Oncology Battle
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - March 24, 2026) - Investorideas.com, a go-to investing platform, releases an industry snapshot looking at advancements in novel immun...
Aethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB Review
SAN DIEGO, March 24, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a clinical-stage biotechnology company developing the investigational Aethlon Hemopurifier®, an extracorporeal device fo...
Aethlon Medical Transcript: Life Sciences Virtual Investor Forum
Hemopurifier, a unique device targeting cancer-related EVs, is progressing through a safety trial in Australia with positive early data and a strong cash position. Key milestones include advancing to an efficacy trial and seeking strategic partnerships for broader development.
Aethlon Medical Engages Maxim Group LLC to Evaluate Strategic Opportunities
SAN DIEGO, March 12, 2026 /PRNewswire/ -- Aethlon Medical, Inc. ("Aethlon" or the "Company") (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threa...
Aethlon Medical to Present at the Life Sciences Investor Forum on March 12th
The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at VirtualInvestorC...
Aethlon Medical Transcript: Emerging Growth Virtual Conference
Hemopurifier clinical trials are advancing in Australia, focusing on solid tumor patients unresponsive to immunotherapy. Operational improvements and new patient recruitment strategies have accelerated progress, with key safety and efficacy data expected in the coming months.
Aethlon Medical to Present on the Emerging Growth Conference on February 25th 2026
Aethlon invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation on the Emerging Growth Conference. SAN DIEGO, Feb. 23, 2026 /...
Aethlon Medical Earnings Call Transcript: Q3 2026
Australian oncology trial for Hemopurifier advanced with strong patient recruitment and cost controls. Operating expenses fell 27% year-over-year for the nine-month period, and compatibility work with the SLAMB system could broaden future clinical use.
Aethlon Medical Announces Fiscal Q3 2026 Financial Results and Corporate Update
Clinical and research programs continue to advance, supported by year-to-date cost efficiencies Conference Call Today at 4:30 p.m. ET SAN DIEGO, Feb. 12, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (th...
Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2026
SAN DIEGO, Feb. 4, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, tod...
Aethlon Medical Announces Pricing of a Private Placement and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $3.3 Million
SAN DIEGO , Dec. 5, 2025 /PRNewswire/ -- Aethlon Medical, Inc. ("Aethlon" or the "Company") (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threat...
Aethlon Medical Announces Publication of Preclinical Data Showing That the GNA Affinity Resin in the Hemopurifier® Binds to Extracellular Vesicles in Long COVID patient samples and Decreases Inflammatory microRNAs
Results Support the Further Investigation of the Hemopurifier in Long COVID SAN DIEGO , Dec. 2, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on deve...
Aethlon Medical Earnings Call Transcript: Q2 2026
Q2 2026 saw a 48% reduction in operating expenses and progress in the Australian oncology trial, with cohort one showing positive safety data and cohort two recruitment underway. Focus remains on oncology and Long COVID, with ongoing efforts to optimize spending and accelerate trial enrollment.
Aethlon Medical Announces Fiscal Q2 2025 Financial Results and Corporate Update
Clinical and research progress continues alongside substantial cost reductions. Conference Call Today at 4:30 p.m.
Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 12, 2025
SAN DIEGO , Nov. 7, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, to...
Aethlon Medical's Hemopurifier® shows Changes in Extracellular Vesicles, Extracellular MicroRNAs, and T Cell Numbers in Australian Oncology Clinical Trial
SAN DIEGO , Oct. 7, 2025 /PRNewswire/ -- Aethlon Medical, Inc. ("Aethlon" or the "Company") (Nasdaq: AEMD) today provided observations on the preliminary changes in extracellular vesicle (EV), microRN...
Aethlon Medical Announces Pricing of $4.5 Million Public Offering
SAN DIEGO , Sept. 4, 2025 /PRNewswire/ -- Aethlon Medical, Inc. ("Aethlon" or the "Company") (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threa...
Aethlon Medical Announces Issuance of Hemopurifier® Patents for the Treatment of Long COVID and COVID-19-associated Coagulopathy (CAC)
SAN DIEGO , Sept. 3, 2025 /PRNewswire/ -- Aethlon Medical, Inc. ("Aethlon" or the "Company") (Nasdaq: AEMD) announced that U.S. Patent No.
Aethlon Medical Earnings Call Transcript: Q1 2026
First cohort of the Australian oncology trial completed with no serious adverse events; cost-saving measures reduced operating expenses by 32% year-over-year. Focus remains on advancing the Hemopurifier program in Australia, with additional funding needs anticipated.
Aethlon Medical Announces Financial Results for the Fiscal First Quarter Ended June 30, 2025, and Provides Corporate Update
Australian Cancer Trial Advances with First Cohort Complete, Amended Protocol, and Promising Preclinical Data Published; Operating Expenses Cut by 32% Conference Call to be Held Today at 4:30 p.m. ET ...
Aethlon Medical to Release Fiscal First Quarter Financial Results and Host Conference Call on August 13, 2025
SAN DIEGO , Aug. 5, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, to...
Aethlon Medical, Inc. Announces Positive Data Safety Monitoring Board Review and Recommendation to Advance to Next Clinical Trial Cohort
SAN DIEGO , July 15, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a clinical-stage biotechnology company developing the investigational Aethlon Hemopurifier®, an extracorporeal device fo...
Aethlon Medical Earnings Call Transcript: Q4 2025
Clinical progress advanced with first oncology patients treated in Australia and regulatory approval in India. Operating expenses dropped 26% year-over-year, with $2.3M raised via warrant inducement. Focus remains on oncology, with preliminary trial data expected in the coming months.
Aethlon Medical Announces Financial Results for the Fiscal Fourth Quarter Ended March 31, 2025, and Provides Corporate Update
Three Patients Treated in Hemopurifier® Cancer Trial; Indian Regulatory Approval Achieved; Operating Expenses Reduced; R&D Advances Support Expanded Indications Including Long COVID Conference Call to...